# TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers

> **NCT01001247** · PHASE1 · COMPLETED · sponsor: **Tibotec Pharmaceuticals, Ireland** · enrollment: 18 (actual)

## Conditions studied

- HIV Infections

## Interventions

- **DRUG:** TMC278; Omeprazole

## Key facts

- **NCT ID:** NCT01001247
- **Lead sponsor:** Tibotec Pharmaceuticals, Ireland
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-01
- **Primary completion:** 2010-04
- **Final completion:** 2010-04
- **Target enrollment:** 18 (ACTUAL)
- **Last updated:** 2010-07-09


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01001247

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01001247, "TMC278-TiDP6-C154: Evaluation of the Possible Influence of Omeprazole Intake - and the pH Increase in the Stomach Triggered by Omeprazole Intake - on the Blood Levels of TMC278 in Healthy Volunteers". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01001247. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*